VIVUS Inc. (VVUS)

4.04
0.13 3.32
NASDAQ : Health Technology
Prev Close 3.91
Open 3.87
Day Low/High 3.76 / 4.10
52 Wk Low/High 2.15 / 5.78
Volume 68.34K
Avg Volume 113.80K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 41.19M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

EBay, McDonald's, Capital 1, Apple Big Movers

EBay, McDonald's, Capital 1, Apple, Popular are among big market movers

Stocks Extend Rally

Stocks Extend Rally

Stocks finish modestly higher Wednesday as Steve Jobs takes the Apple stage but fall off their highs after the Fed's beige book.

Top Takes From RealMoney

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

Rising Commodities Push Industrial Stocks Higher

Rising Commodities Push Industrial Stocks Higher

US stocks rise as commodities prices rally, dollar stays near recent lows; industrials climb

Big Weight Loss for Vivus Drug: BioBuzz

Big Weight Loss for Vivus Drug: BioBuzz

The weight-loss results were impressive from two pivotal studies of Vivus' obesity drug Qnexa.

Vivus' Qnexa Reduces Weight In Key Obesity Studies

Vivus' Qnexa Reduces Weight In Key Obesity Studies

Vivus' obesity drug candidate hits weight reduction goals in 2 late-stage studies; shares soar

Vivus To Report Late-stage Qnexa Data Wednesday

Vivus To Report Late-stage Qnexa Data Wednesday

Vivus says it will announce data from 2 clinical trials of obesity drug candidate Qnexa

Hot Biotech Events for Next Week: BioBuzz

Investor conferences and phase III data on tap for post-Labor Day

In Research Mode

Taking advantage of this seasonally slow period to take a closer look at some potential names for the model portfolio.

Earnings Roundup: Clearwire, Celadon

Earnings Roundup: Clearwire, Celadon

Earnings roundup: Clearwire 2Q loss shrinks, Celadon Group 4Q profit drops 92 percent

No Stopping Chipmaker Rally

No Stopping Chipmaker Rally

Guests include TheStreet.com Breakout Stocks editor Bryan Ashenberg, TheStreet.com Stocks Under $10 editor David Peltier and RealMoney.com contributor Don Dion.

Weighing New Possibilities

Researching biopharmaceutical names in the anti-obesity drug sector as potential additions to the model portfolio.

Orexigen's Contrave Takes Off the Weight

Obesity patients treated with a weight-loss combination pill from Orexigen Therapeutics lost an average of more than 13 pounds, or just more than 6% of their body weight, after one year of treatment, studies show.

Biotech Calendar: More Key Clinical Trial Dates

Biotech Calendar: More Key Clinical Trial Dates

Another quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.

Earnings Roundup: Fossil, Vivus

Earnings Roundup: Fossil, Vivus

Earnings roundup: Fossil 1Q net down, but hikes full-year outlook; Vivus 1Q loss shrinks

Vivus 1Q Loss Narrows On Lower Development Costs

Vivus 1Q Loss Narrows On Lower Development Costs

Vivus posts smaller 1st-quarter loss on lower development costs for obesity drug candidate

Arena Defends Obesity Drug as Stock Plunges

Arena Pharmaceuticals reported phase III trial data for obesity drug lorcaserin that did not hit all FDA standards.

Arena Shares Fall As Drug Misses An FDA Benchmark

Arena Pharmaceuticals shares drop as obesity drug falls shy of a proposed FDA benchmark

Biotech Stock Mailbag: Fans Rally 'Round Arena

Arena fans take issue with a column outlining the company's challenges.

Obesity Drug Arena's Heavy Burden

Drug company Arena Pharmaceuticals is under pressure to produce stellar results from a phase III study of its obesity drug later this month.

TSC Ratings' Updates: Inergy

TSC Ratings' Updates: Inergy

Inergy is upgraded; Chubb, CB Richard Ellis Group, Equity Residential and CNA Financial are downgraded.

Vivus falls to 4Q loss on rising Qnexa costs

Vivus posts 4th-quarter loss after doubling research spending as Qnexa trials continue

Orexigen Tanks After-Hours on Obesity Data

Obesity patients treated with a weight-loss pill from Orexigen Therapeutics lost an average of 20.3 pounds, or 9.3% of their body weight, over one year, according to results from a phase III study released Thursday.

Orexigen to Post Obesity Data in Race With Vivus, Arena

Orexigen Therapeutics is expected to release the first phase III data on its experimental weight-loss drug Contrave ahead of a key investor presentation Monday.

Vivus: Obesity Drug Data Satisfy Goals

Vivus: Obesity Drug Data Satisfy Goals

Phase III study shows patients treated with a high dose of Qnexa lost 7.5% of their body weight adjusted for placebo.

Single Drugmakers Seek Rich Partners

Single Drugmakers Seek Rich Partners

Scores of smaller biotech firms have unpartnered drugs in the pipeline, making them ripe for alliances or takeovers.

Orexigen Execs Quit on Heels of Obesity Drug Data

Orexigen Execs Quit on Heels of Obesity Drug Data

The drugmaker is losing three executives and ending two trials weeks before it releases results of a pivotal obesity drug study.

Vivus to Roll Out Key Obesity Drug Data

Vivus to Roll Out Key Obesity Drug Data

The pending results from two studies of Vivus' drug Qnexa is just the start of what promises to be an active 12 months in the race to develop the next generation of obesity drugs.

Diabetes-Drug Makers Face FDA Hurdle

Diabetes-Drug Makers Face FDA Hurdle

The regulatory agency is alerting diabetes-drug makers, like Amylin, of new heart-safety data standards.

Health Winners & Losers: Vivus

Health Winners & Losers: Vivus

Amylin is down 20.1%.

TheStreet Quant Rating: D (Sell)